Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Completed · Phase 2
Conditions studied: Graft vs Host Disease, Blood and Marrow Transplant (BMT)
In brief
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Key facts
- Study ID
- NCT00186667
- Run by
- Stanford University
- People needed
- 30
- Starts
- 1999-01-01
- Expected to finish
- 2005-09-01
- Last updated by the study team
- 2020-04-09
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.